Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 3.1% – What’s Next?

Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) traded down 3.1% on Wednesday . The company traded as low as $1.5650 and last traded at $1.58. 1,129,796 shares traded hands during trading, an increase of 34% from the average session volume of 844,595 shares. The stock had previously closed at $1.63.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on LCTX shares. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, November 25th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, November 24th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $4.67.

Lineage Cell Therapeutics Stock Performance

The company has a fifty day moving average of $1.69 and a two-hundred day moving average of $1.51. The firm has a market capitalization of $363.92 million, a price-to-earnings ratio of -5.45 and a beta of 1.74.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.30 million. Lineage Cell Therapeutics had a negative return on equity of 72.02% and a negative net margin of 625.53%. Equities analysts forecast that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth approximately $25,000. Integrity Alliance LLC. grew its position in Lineage Cell Therapeutics by 75.0% during the second quarter. Integrity Alliance LLC. now owns 35,000 shares of the company’s stock worth $32,000 after buying an additional 15,000 shares in the last quarter. Citizens Financial Group Inc. RI bought a new position in Lineage Cell Therapeutics during the 3rd quarter worth $25,000. Red Crane Wealth Management LLC increased its stake in Lineage Cell Therapeutics by 3.1% during the 3rd quarter. Red Crane Wealth Management LLC now owns 511,363 shares of the company’s stock worth $864,000 after acquiring an additional 15,365 shares during the period. Finally, Rhumbline Advisers raised its holdings in Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after acquiring an additional 18,092 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.